Sep 30, 2019 8:45am EDT Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
Sep 09, 2019 8:00am EDT United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4
Aug 27, 2019 8:00am EDT Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients
Aug 01, 2019 7:15am EDT Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update
Jul 29, 2019 4:05pm EDT Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019
Jul 25, 2019 8:00am EDT Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
Jul 22, 2019 8:00am EDT Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
Jul 18, 2019 8:00am EDT Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
Jun 27, 2019 8:00am EDT Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
